My Neurosurgeon used this during resection 2 years ago and I believe it is a strong contributor to my 99% resection.Marc
Is it expected to improve outcomes overall?
Yes, a more complete resection would be expected to improve survival. In the original phase 3 trial in Europe, contrast enhancing tumor was completely resected in 65% of patients in the 5-ALA arm versus 36% in the control arm. Progression-free survival at 6 months was 41% in the 5-ALA arm versus 21% in the control arm. This is why it was approved in Europe 10 YEARS ago. Finally the US catches up.
But I think I read somewhere it is more useful in GBM, not so much in LGG
Yes, I believe the intact BBB in LGG prevents it from being taken up by the tumor.
One study showed most (83%) of WHO grade 2 gliomas don't show fluorescence after 5-ALA treatment.https://www.ncbi.nlm.nih.gov/pubmed/26366972However one study proposed enhanced 5-ALA fluorescence in IDH1 mut gliomas, although this was based on genetically engineered U87 cells.https://www.ncbi.nlm.nih.gov/pubmed/26008980
Dr Colin Watts, a neurosurgeon from Cambridge England, discusses 5-ALA in a 2013 youtube video. The 5-ALA bit starts about 24:40.https://www.youtube.com/watch?v=FKRLjh1H28k